DALLAS, Feb. 26, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a patient based U.S. company targeting critical and non-critical ailments through the use of Cannabinoid based formulations, extracts, and products through multiple Phytiva Brand product lines and solutions, strongly encourages like-minded citizens to contact their elected officials in support of safe access to cannabinoids for medical use in conjunction with the "lobby day" efforts of the Americans for Safe Access (ASA) National Medical Cannabis Unity Conference 2013 held in Washington, D.C. during the last four days.
Consistent with the findings and discussions at the ASA conference, the Company has already publicly launched two initiatives in this area with its Phytiva Brand European Cannabinoid product line and its Cannabinoid treatment-based facility development agreement with the Maliseet Nation in Eastern Canada.
"As an ASA conference participant, it is clear that the time is now to persuade our regulatory authorities of the proven efficacy of cannabinoid based medicine, products, and treatments. These therapies are already being utilized in the U.S. and around the world in a successful, rigorous, and professional manner. It is in the interest of human healthcare to support these cannabinoid efforts and to place an even greater emphasis on increasing research into the healing properties of cannabinoids," stated Chad S. Johnson, Chief Operating Officer and General Counsel of X-Change Corp.
The ASA conference successfully brought together medical cannabinoid patients and supportive medical professionals, scientists, attorneys, policy experts, politicians, and other stakeholders in the medical cannabinoid space to create an environment for enhancing and expanding safe access to life-saving medicines and treatments. With the positively shifting ground around medical cannabinoids, this conference located in the nation's capital, continued to move the U.S. down the rational path of cannabinoid acceptance and use. More information about the mission, agenda and participants of the ASA conference is available at http://safeaccessnow.org/blog/conference2013/. With more than eighty percent (80%) of Americans in favor of cannabinoid medicine, the Company is well positioned as a corporation and as a socially responsible entity to continue the Company's leadership in this burgeoning international industry.
About Phytiva Brand Product Lines
Phytiva expects to develop and launch various innovative product lines. The first is the Phytiva Brand European Line, which is an inventive line that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a Cannabinoid based product line, utilizing the unique and potent benefits of Cannabinoids. Phytiva's revolutionary formulations target not just the symptom, but also the cause. Cannabinoids and their sources constitute an ideal base for therapeutic solutions and have been utilized for centuries in skin and other remedies.
In the near term, Phytiva strives to be one of the quintessential cosmeceutical and nutraceutical brands in the world. As cosmetics and nutrition are personal, over-the-counter markets, they continuously evolve with the introduction of new formulations and products, creating a multibillion-dollar global market opportunity. The Company believes that Phytiva's lines will capture a substantial and profitable portion of that market, as Phytiva becomes a household name.
About The X-Change Corporation
X-Change Corp. is U.S. Boutique Company whose niche is Cannabinoid based extracts and products that target medical cannabis, cosmeceutical, nutraceutical, and social usage solutions through multiple Phytiva Brand product lines, products, and services. These new Phytiva lines will be launched with Cannabinoid based formulations through the launching of a combination of retail and wholesale products, medical cannabis dispensaries, cannabis research in clinics and laboratories, as announced for example with the Maliseet Nation in Canada, and other legal state and foreign grow operations, on a jurisdiction by jurisdiction approved basis.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE X-Change Corp.